Raine Syndrome: Disease Characteristics Research Report

Executive summary

Raine syndrome (RNS) is an ultra-rare, autosomal-recessive skeletal dysplasia caused by biallelic loss-of-function variants in FAM20C, which encodes a Golgi-associated kinase responsible for phosphorylating many secreted proteins. Its spectrum extends from a severe congenital form—characterized by generalized osteosclerosis, distinctive craniofacial abnormalities, intracranial calcification, pulmonary hypoplasia, and death in early infancy—to nonlethal disease with hypophosphatemic rickets/osteomalacia, neurological disability, hearing or visual impairment, and major dental/gingival disease. A 2021 literature synthesis counted 70 reported patients: 41 lethal and 29 nonlethal; prevalence remains estimated at less than 1 per million. These figures reflect published cases rather than population-based surveillance and are therefore vulnerable to ascertainment bias. (costa2024gingivalproteomicsreveals pages 1-2, palmalara2021fam20coverviewclassic pages 1-2)

Recent work has expanded the disease beyond a simple osteosclerotic dysplasia. A 2023 computational study proposed brain-relevant FAM20C substrates involving cholesterol/lipoprotein biology and axodendritic transport; a 2023 mouse study reproduced intracranial calcification; and a 2024 human gingival proteomics study identified a TGFβ–SMAD–YAP/TAZ profibrotic loop in affected gingiva. (palmalara2023potentialroleof pages 1-2, costa2024gingivalproteomicsreveals pages 2-3, costa2024gingivalproteomicsreveals pages 1-2)

Table: This compact table summarizes the main knowledge-base elements for Raine syndrome, including identifiers, core phenotypes, mechanisms, anatomy, diagnostics, management, and evidence gaps. It is useful as a structured seed for ontology mapping and curation.

1. Disease information

Definition and classification

Raine syndrome is a Mendelian, autosomal-recessive disorder of secretory-pathway protein phosphorylation, biomineralization, and phosphate homeostasis. It is conventionally classified among osteosclerotic bone dysplasias, although surviving patients can develop hypophosphatemic rickets or osteomalacia alongside radiographic sclerosis. (palmalara2023potentialroleof pages 1-2, costa2024gingivalproteomicsreveals pages 1-2, palmalara2021fam20coverviewclassic pages 1-2)

Principal identifiers and names

• MONDO: MONDO:0009821, labeled “lethal osteosclerotic bone dysplasia” in the retrieved Open Targets mapping.
• OMIM: 259775, Raine syndrome; 259660 is the historical entry “congenital sclerosing osteomalacia with cerebral calcification.”
• Gene-associated name: FAM20C-related osteosclerotic dysplasia.
• Synonyms: Raine syndrome; lethal osteosclerotic bone dysplasia; osteosclerotic bone dysplasia, Raine type; congenital sclerosing osteomalacia with cerebral calcification; lethal and nonlethal Raine syndrome.
• A dedicated, disease-specific ICD-10 or ICD-11 code was not established in the retrieved material; clinically, broader congenital osteochondrodysplasia codes may be used. MeSH and SNOMED CT mappings should be verified directly before production use. (OpenTargets Search: Raine syndrome-FAM20C, palmalara2023potentialroleof pages 26-27, palmalara2021fam20coverviewclassic pages 1-2)

The evidence base is predominantly aggregated disease-level literature assembled from individual case reports and small families, not EHR-derived population data. The 2024 mechanistic study used tissue and primary fibroblasts from only two affected individuals. (costa2024gingivalproteomicsreveals pages 2-3, palmalara2021fam20coverviewclassic pages 1-2)

2. Etiology, risk, and protective factors

Causal factor

The primary cause is germline biallelic loss of FAM20C function. FAM20C is a serine/threonine kinase located mainly in the Golgi/secretory pathway and recognizes secreted-protein motifs including S-X-E/pS. Loss of kinase activity, defective intracellular localization, altered secretion, or protein truncation impairs extracellular phosphoprotein regulation. (palmalara2023potentialroleof pages 1-2, costa2024gingivalproteomicsreveals pages 1-2, palmalara2021fam20coverviewclassic pages 16-17)

Reported variant classes include whole-gene and multiexon deletions, frameshift, nonsense, splice-site, and missense variants. A 2024 summary listed 42 disease-associated variants—22 associated with lethal and 20 with nonlethal disease. Variants abolishing protein or kinase activity tend to produce lethal disease, whereas residual activity is more often compatible with survival; this is a trend rather than a deterministic clinical rule. (costa2024gingivalproteomicsreveals pages 1-2, palmalara2021fam20coverviewclassic pages 16-17)

Risk factors

• Genetic: two pathogenic/likely pathogenic alleles in trans; parental consanguinity raises the probability of homozygosity. Each pregnancy of two confirmed carriers has the standard autosomal-recessive risks: 25% affected, 50% carrier, and 25% unaffected/noncarrier.
• Family history: an affected sibling or known parental carrier status materially increases prior probability.
• Sex, age, and ancestry: no demonstrated sex-specific biological risk or reliable ethnicity-specific prevalence was found.
• Environment, lifestyle, toxins, occupation, or infection: no evidence that any of these causes Raine syndrome.

No validated protective FAM20C allele, modifier gene, lifestyle factor, or gene–environment interaction has been established. Dietary phosphate modified skeletal severity in a mouse model, but that is modification of downstream physiology—not prevention of the genetic disorder. (zhang2020highphosphatedietimproved pages 11-12)

3. Phenotypes

Because published series are small and enriched for severe cases, robust percentages are unavailable for most manifestations. “Common” below means recurrent in reports/reviews, not a population-derived frequency.

Congenital skeletal and craniofacial phenotype

• Generalized osteosclerosis—congenital, often severe in lethal disease; suggested HPO: Osteosclerosis.
• Periosteal bone formation/thickening; HPO term suggestion: Abnormal periosteum morphology.
• Flat facial profile, midface hypoplasia, hypoplastic/depressed nasal bridge, prominent eyes or exophthalmos, low-set ears, microcephaly, and cleft palate; congenital and variably persistent.
• Choanal stenosis/atresia, which can compound neonatal respiratory compromise.
• Craniosynostosis/multisuture synostosis has been documented prenatally in recent severe presentations.
• Long-bone and growth-plate abnormalities can evolve into rickets/osteomalacia in survivors. (palmalara2023potentialroleof pages 1-2, costa2024gingivalproteomicsreveals pages 21-22, palmalara2021fam20coverviewclassic pages 1-2)

Suggested HPO terms include Midface retrusion, Hypoplastic nose, Depressed nasal bridge, Exophthalmos, Low-set ears, Microcephaly, Cleft palate, Choanal atresia, Craniosynostosis, Rickets, and Osteomalacia.

Neurological and neuroimaging phenotype

Intracranial or intracerebral calcification is a hallmark and may be visible prenatally. Other reported findings include enlarged choroid plexuses, echogenic fetal brain, ventricular abnormalities, structural brain malformations, developmental delay, intellectual disability, and seizures. Severity ranges from imaging abnormalities without fully defined functional effect to substantial lifelong neurodevelopmental disability. (palmalara2023potentialroleof pages 1-2, palmalara2021fam20coverviewclassic pages 1-2)

Suggested HPO terms: Intracranial calcification, Cerebral calcification, Structural brain anomaly, Global developmental delay, Intellectual disability, Seizure, and Abnormality of the choroid plexus.

Respiratory phenotype

Pulmonary hypoplasia and respiratory insufficiency are major determinants of neonatal lethality; craniofacial airway obstruction can contribute. Most classic lethal cases die during the first weeks of life. Suggested HPO: Pulmonary hypoplasia, Respiratory insufficiency, Neonatal respiratory distress. (palmalara2021fam20coverviewclassic pages 1-2)

Dental and gingival phenotype

Survivors commonly have hypoplastic amelogenesis imperfecta, abnormal dentin, delayed or abnormal tooth development, gingival overgrowth/fibrosis, and gingival or other ectopic calcifications. These impair mastication, oral hygiene, appearance, speech, and periodontal health and can require repeated dental care. In two 2024 cases, one patient also had visual impairment and the other hearing impairment. (costa2024gingivalproteomicsreveals pages 2-3, costa2024gingivalproteomicsreveals pages 1-2)

Suggested HPO: Amelogenesis imperfecta, Abnormal dentin morphology, Gingival overgrowth, Gingival fibrosis, Ectopic calcification, Visual impairment, and Hearing impairment.

Laboratory abnormalities

Nonlethal disease is associated with hypophosphatemia, FGF23 dysregulation, renal phosphate wasting, and rickets/osteomalacia physiology. Appropriate measurements include fasting serum phosphate interpreted against age-specific ranges, calcium, alkaline phosphatase, PTH, creatinine, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, intact and/or C-terminal FGF23, urine phosphate, tubular maximum phosphate reabsorption/GFR, and renal ultrasound for nephrocalcinosis. Exact disease-specific reference ranges or sensitivities have not been established. (palmalara2023potentialroleof pages 1-2, costa2024gingivalproteomicsreveals pages 21-22, zhang2020highphosphatedietimproved pages 11-12)

No validated Raine-specific quality-of-life instrument or EQ-5D/SF-36 dataset was found.

4. Genetic and molecular information

Causal gene: FAM20C, encoding FAM20C Golgi-associated secretory-pathway kinase; Ensembl target ENSG00000177706. The variants are constitutional/germline, not somatic drivers. (OpenTargets Search: Raine syndrome-FAM20C)

The pathogenic mechanism is predominantly loss of function through absent protein, truncation/nonsense-mediated decay, catalytic impairment, mislocalization, or defective secretion. Among 22 exclusively lethal variants summarized in a 2021 review, absent/nonsense/truncated forms were the largest category, including homozygous whole-gene deletions and a reported approximately 487-kb 7p22 deletion. (palmalara2021fam20coverviewclassic pages 16-17)

The 2024 gingival study examined two nonlethal genotypes: p.Pro496Leu, predicted to disrupt the activation loop, and a splice-associated p.Trp202Cysfs* product yielding a 239-amino-acid truncated protein. Variant interpretation should nevertheless use current ACMG/AMP criteria, segregation, population frequency, phenotype match, and functional evidence rather than the publication’s phenotype alone. (costa2024gingivalproteomicsreveals pages 2-3)

Pathogenic alleles are expected to be individually rare or absent from large population databases, but no comprehensive gnomAD allele-frequency table was retrieved. No validated modifier genes, protective alleles, disease-specific methylation signature, repeat expansion, recurrent aneuploidy, or somatic mosaic mechanism is established. Large deletions encompassing FAM20C can cause disease, so copy-number analysis is necessary when sequencing detects only one allele. (palmalara2021fam20coverviewclassic pages 16-17)

5. Environmental information

Raine syndrome is not known to be caused or triggered by toxins, radiation, pollution, smoking, alcohol, diet, exercise, occupational exposure, bacteria, viruses, fungi, or parasites. Environment can influence complications—for example, phosphate intake, dental hygiene, respiratory infection burden, and access to specialist care—but evidence for disease-specific gene–environment interaction is absent. There is no zoonotic or transmissible component.

6. Mechanism and pathophysiology

Causal chain

1. Upstream genetic defect: biallelic FAM20C loss-of-function.
2. Subcellular defect: reduced Golgi/secretory-pathway kinase activity, with some variants causing ER retention or altered localization.
3. Substrate defect: hypophosphorylation of secreted phosphoproteins, including SIBLING-family biomineralization proteins and proteins involved in FGF23 processing.
4. Systemic consequences: disordered extracellular-matrix mineralization and abnormal FGF23/phosphate homeostasis.
5. Tissue outcomes: osteosclerosis and periosteal abnormalities prenatally, followed in survivors by renal-phosphate-wasting hypophosphatemia, rickets/osteomalacia, dental mineralization defects, ectopic calcification, and neurological abnormalities.
6. Clinical outcomes: craniofacial dysplasia, respiratory failure in severe neonatal disease, chronic skeletal/dental disability, and variable neurodevelopmental impairment. (palmalara2023potentialroleof pages 1-2, costa2024gingivalproteomicsreveals pages 1-2, zhang2020highphosphatedietimproved pages 11-12)

FAM20C phosphorylates more than 90–100 secreted or body-fluid proteins, supporting a multisystem phosphoproteinopathy rather than a bone-exclusive disorder. Suggested GO annotations include protein phosphorylation, extracellular matrix organization, biomineral tissue development, regulation of phosphate ion homeostasis, skeletal system development, and tooth mineralization. Relevant compartments are Golgi apparatus, Golgi lumen, endoplasmic reticulum, secretory vesicle, and extracellular region. (palmalara2023potentialroleof pages 1-2, palmalara2021fam20coverviewclassic pages 1-2)

2024 human proteomics development

Costa et al. used gingival tissue, primary gingival fibroblasts, label-free LC-MS/MS proteomics, immunomorphology, biochemistry, and siRNA in two unrelated patients. They found excessive/disorganized ECM, fibrosis, pathological calcification, and increased POSTN, SPARC, and VIM. TGFβ/SMAD signaling and YAP/TAZ cofactors were activated; FAM20C knockdown supported a self-reinforcing profibrotic loop. Mutant fibroblasts showed enhanced ER colocalization and loss of normal cis-Golgi association. This is direct human tissue and cell evidence, but sample size was two. (costa2024gingivalproteomicsreveals pages 2-3, costa2024gingivalproteomicsreveals pages 1-2)

The authors’ abstract states: “They furthermore uncover the contribution of increased TGFβ–YAP/TAZ signaling in the pathogenesis of the gingival fibrosis.” [Scientific Reports, 12 April 2024; DOI: https://doi.org/10.1038/s41598-024-59713-0]. (costa2024gingivalproteomicsreveals pages 1-2)

Brain mechanisms

The 2023 computational analysis linked highly expressed brain targets/interactors to cholesterol and lipoprotein processes, axodendritic transport, and neuronal compartments. These are hypothesis-generating associations, not proof that any individual substrate causes seizures or intellectual disability. Suggested GO terms include axon transport, dendrite development, and cholesterol metabolic process; suggested CL terms include neuron, astrocyte, and choroid plexus epithelial cell, although direct cell-specific causality remains unproven. [Published 17 May 2023; DOI: https://doi.org/10.3390/ijms24108904]. (palmalara2023potentialroleof pages 1-2)

No disease-specific single-cell, spatial transcriptomic, lipidomic, metabolomic, CRISPR-screen, or integrated multi-omic human study was identified.

7. Anatomical structures affected

Primary sites are the craniofacial skeleton, skull sutures, long bones and growth plates, teeth, dentin, enamel, gingiva/periodontium, and brain/intracranial tissues. The choanae, upper airway, lungs, eyes, ears, and kidneys may be involved directly or through complications. Disease is usually systemic and bilateral rather than consistently lateralized. (palmalara2023potentialroleof pages 1-2, costa2024gingivalproteomicsreveals pages 2-3, palmalara2021fam20coverviewclassic pages 1-2)

Suggested UBERON terms: craniofacial skeleton, calvaria, cranial suture, long bone, growth plate cartilage, tooth, enamel, dentin, gingiva, periodontal ligament, brain, choroid plexus, choana, lung, and kidney. Suggested CL terms: osteoblast, osteocyte, chondrocyte, odontoblast, ameloblast, gingival fibroblast, and neuron. The best directly demonstrated human cell type in recent work is the gingival fibroblast. (costa2024gingivalproteomicsreveals pages 2-3, costa2024gingivalproteomicsreveals pages 1-2)

8. Temporal development

The severe phenotype begins prenatally. Ultrasound may reveal a flat profile, hypoplastic nose, prominent eyes, echogenic brain, enlarged choroid plexus, ventricular changes, intracranial calcification, and craniosynostosis. Neonatal disease can progress rapidly to respiratory death. (palmalara2021fam20coverviewclassic pages 1-2)

Nonlethal disease is congenital but chronic and variably progressive. Skeletal findings can shift from early osteosclerosis to hypophosphatemic rickets/osteomalacia; dental and gingival abnormalities emerge with tooth development, while developmental disability or seizures may become apparent in childhood. Adult survival—including middle-aged and elderly patients—has been reported, but no formal stages, remission pattern, median survival, or validated longitudinal progression rate exists. (costa2024gingivalproteomicsreveals pages 1-2, costa2024gingivalproteomicsreveals pages 21-22)

Critical clinical windows are prenatal recognition, immediate neonatal airway assessment, childhood growth and phosphate monitoring, tooth eruption, and ongoing neurological surveillance. There is no evidence of spontaneous molecular remission.

9. Inheritance and population

Inheritance is autosomal recessive. Penetrance for individuals with two severe pathogenic alleles appears high, but allele-specific penetrance has not been quantified. Expressivity is markedly variable. Anticipation is not expected; no repeat-expansion mechanism exists. Germline mosaicism is theoretically possible but not established as a recurrent feature. (costa2024gingivalproteomicsreveals pages 1-2, palmalara2021fam20coverviewclassic pages 1-2)

The estimated prevalence is <1 per 1,000,000. A 2021 review found 70 published patients—41 lethal and 29 nonlethal—while a 2024 paper summarized 42 variants. Neither statistic represents incidence or a complete global registry. Consanguinity is recurrent in autosomal-recessive case literature, but no population-specific founder allele, carrier frequency, geographic hotspot, sex ratio, or robust incidence estimate was identified. (costa2024gingivalproteomicsreveals pages 1-2, palmalara2021fam20coverviewclassic pages 1-2)

10. Diagnostics

Recommended approach

1. Clinical recognition: congenital craniofacial phenotype, osteosclerosis, intracranial calcification, choanal obstruction, neonatal respiratory compromise, or—later—hypophosphatemia with osteosclerosis plus enamel/dentin and gingival abnormalities.
2. Imaging: prenatal ultrasound; fetal MRI where available; postnatal skeletal survey/radiographs; low-dose cranial CT when calcification detection is essential; brain MRI for anatomy; renal ultrasound for nephrocalcinosis.
3. Biochemistry: phosphate/FGF23 and mineral metabolism panel as described above.
4. Molecular confirmation: sequencing and deletion/duplication analysis of FAM20C. A skeletal-dysplasia, craniosynostosis, hypophosphatemia, or amelogenesis-imperfecta panel is reasonable. WES/WGS is appropriate when the phenotype is atypical or panel testing is negative.
5. Family studies: parental segregation, carrier testing, and testing of at-risk siblings. (palmalara2023potentialroleof pages 26-27, palmalara2021fam20coverviewclassic pages 1-2, costa2024gingivalproteomicsreveals pages 2-3)

Sanger single-gene testing is useful for a known familial variant. CMA can detect larger 7p22 deletions but may miss sequence variants; karyotyping and FISH are not first-line unless a structural rearrangement is suspected. Mitochondrial, repeat-expansion, liquid-biopsy, proteomic, and methylation testing are not established diagnostic methods. No validated clinical scoring criteria or biochemical biomarker with known sensitivity/specificity exists.

Differential diagnosis

Important alternatives include other osteosclerosing dysplasias and craniotubular disorders, osteopetrosis, pyknodysostosis, dysosteosclerosis, infantile hypophosphatasia, congenital infections and interferonopathies causing intracranial calcification, primary familial brain calcification, hypophosphatemic rickets syndromes, and enamel-renal syndrome due to FAM20A. The combination of biallelic FAM20C variants with osteosclerosis, cerebral calcification, craniofacial dysplasia, and dental/phosphate abnormalities is distinguishing.

Suggested MAXO actions: molecular genetic testing, exome sequencing, genome sequencing, deletion/duplication analysis, prenatal ultrasound, fetal MRI, skeletal radiography, cranial CT, brain MRI, and serum phosphate measurement.

11. Outcome and prognosis

The classic form often causes death within the first weeks from pulmonary hypoplasia and respiratory failure. No reliable 5- or 10-year survival estimate exists. Survivors may live into adulthood but can experience chronic rickets/osteomalacia, impaired growth or mobility, bone pain, neurodevelopmental disability, seizures, sensory impairment, and extensive dental/periodontal morbidity. (palmalara2021fam20coverviewclassic pages 1-2, costa2024gingivalproteomicsreveals pages 2-3)

Likely adverse prognostic indicators are severe prenatal osteosclerosis, pulmonary hypoplasia, major airway obstruction, multisuture craniosynostosis, extensive brain abnormalities, and variants leaving little or no kinase activity. Residual function is generally associated with nonlethal disease, but individual prognosis should not be inferred from variant class alone. No validated prognostic biomarker or disease-specific patient-reported outcome measure exists. (costa2024gingivalproteomicsreveals pages 1-2, palmalara2021fam20coverviewclassic pages 16-17)

12. Treatment and current applications

There is no approved curative or FAM20C-directed therapy, published treatment algorithm, or disease-specific pharmacogenomic guideline.

• Neonatal care: airway stabilization, respiratory support, management of choanal obstruction, feeding support, and palliative-care involvement when disease is lethal.
• Metabolic bone care: individualized phosphate and active-vitamin-D management may be considered for FGF23-mediated hypophosphatemia, with close monitoring of calcium, PTH, urine calcium, renal function, and nephrocalcinosis. Human response rates specific to Raine syndrome are unavailable.
• Dental/periodontal care: preventive dentistry, restoration/prosthodontics as appropriate, treatment of gingival overgrowth and periodontitis, and multidisciplinary management of amelogenesis imperfecta.
• Developmental care: physical, occupational, speech/feeding, hearing, vision, and neurological services.
• Surgery: individualized correction of choanal atresia, craniosynostosis, cleft palate, or severe orthopedic deformity; disease-specific outcome series are absent.

Suggested MAXO terms include respiratory support, assisted ventilation, phosphate supplementation, active vitamin D therapy, dental surveillance, periodontal treatment, physical therapy, occupational therapy, speech therapy, hearing assessment, vision assessment, and genetic counseling.

In Fam20c-deficient mice, a high-phosphate diet improved long-bone shape and mineral density and nearly normalized growth-plate widening. The abstract concludes: “These results suggested that the hPi diet significantly improved the skeletal development of the Fam20c-deficient mice, implying that hypophosphatemia partially contributed to the skeletal defects.” This is preclinical evidence and does not establish safety or efficacy in humans. [Published February 2020; DOI: https://doi.org/10.1159/000506005]. (zhang2020highphosphatedietimproved pages 11-12)

A ClinicalTrials.gov search found no trial whose condition was genuinely Raine syndrome; records using “RNS” for neuromodulation were acronym collisions. Gene replacement, CRISPR editing, RNA therapies, cell therapies, immunotherapy, and anti-FGF23 therapy remain unvalidated for this disease.

13. Prevention

The genotype cannot be prevented by lifestyle or vaccination. Evidence-based prevention is reproductive and complication-directed:

• carrier and cascade testing after a molecular diagnosis;
• genetic counseling with 25% recurrence-risk discussion for carrier couples;
• targeted prenatal diagnosis by chorionic-villus sampling or amniocentesis;
• preimplantation genetic testing for a known familial variant;
• detailed prenatal imaging in at-risk pregnancies;
• early respiratory, phosphate, renal, dental, hearing, vision, and developmental surveillance;
• tertiary prevention of rickets, nephrocalcinosis, dental infection, periodontal disease, contractures, and developmental complications.

Population newborn biochemical screening is not available. Expanded genomic screening could detect FAM20C variants, but interpretation, prevalence, and clinical utility have not been established.

14. Other species and natural disease

No well-established naturally occurring veterinary analogue or zoonotic form was identified. FAM20C orthologues are evolutionarily conserved across vertebrates, and related secretory-pathway kinase activity also exists in Drosophila. Comparative data support conservation of extracellular phosphoprotein and biomineralization biology, but experimental models should not be described as naturally transmitted disease. Suggested taxonomy terms include Homo sapiens and Mus musculus; the exact NCBI Gene identifiers should be verified in NCBI Gene before database ingestion.

15. Model organisms and experimental systems

Mouse: global or conditional Fam20c deficiency reproduces hypophosphatemia, elevated FGF23, rickets/osteomalacia-like skeletal defects, abnormal dentin/enamel, and intracranial calcification. The 2023 study specifically showed that intracranial calcification in Fam20c-deficient mice recapitulates a defining human feature. [Neuroscience Letters, April 2023; DOI: https://doi.org/10.1016/j.neulet.2023.137176]. These models are useful for phosphate physiology, mineralized tissues, brain calcification, and preclinical dietary interventions, but they do not capture the full human lethal craniofacial/respiratory spectrum. (palmalara2023potentialroleof pages 1-2, zhang2020highphosphatedietimproved pages 11-12)

Human cell systems: primary gingival fibroblasts and siRNA-mediated FAM20C knockdown model ECM disorganization and the TGFβ–YAP/TAZ fibrotic loop. Their strength is direct patient relevance; limitations include only two genotypes and one tissue lineage. (costa2024gingivalproteomicsreveals pages 2-3, costa2024gingivalproteomicsreveals pages 1-2)

In-vitro kinase systems: recombinant FAM20C experiments establish phosphorylation of secreted biomineralization proteins and show that disease-associated substitutions impair localization or kinase activity. This supplies biochemical causality but cannot alone predict organismal severity. The foundational abstract states: “Our results identify FAM20C as a kinase for secreted phosphoproteins and establish a biochemical basis for Raine syndrome.” [Published 13 August 2012; DOI: https://doi.org/10.1371/journal.pone.0042988]. (palmalara2023potentialroleof pages 1-2)

Evidence appraisal and knowledge gaps

The strongest conclusions are the biallelic FAM20C etiology, autosomal-recessive inheritance, core skeletal/craniofacial/calcification phenotype, and secretory-pathway kinase mechanism. Major limitations are extreme rarity, case-report ascertainment, inconsistent laboratory reporting, incomplete functional characterization of variants, and the absence of registries, controlled treatment trials, standardized diagnostic criteria, longitudinal quality-of-life data, or validated prognostic models. The 2023–2024 studies materially advance mechanism but do not yet change standard clinical care. (costa2024gingivalproteomicsreveals pages 1-2, costa2024gingivalproteomicsreveals pages 2-3, palmalara2023potentialroleof pages 1-2)

Key recent and foundational sources

• Costa et al. Gingival proteomics reveals the role of TGF beta and YAP/TAZ signaling in Raine syndrome fibrosis. Scientific Reports. Published April 2024. https://doi.org/10.1038/s41598-024-59713-0. (costa2024gingivalproteomicsreveals pages 2-3, costa2024gingivalproteomicsreveals pages 1-2)
• Zhang et al. Intracranial calcification in Fam20c-deficient mice recapitulates human Raine syndrome. Neuroscience Letters. Published April 2023. https://doi.org/10.1016/j.neulet.2023.137176. (palmalara2023potentialroleof pages 1-2)
• Palma-Lara et al. Potential Role of Protein Kinase FAM20C on the Brain in Raine Syndrome, an In Silico Analysis. International Journal of Molecular Sciences. Published 17 May 2023. https://doi.org/10.3390/ijms24108904. (palmalara2023potentialroleof pages 1-2)
• Palma-Lara et al. FAM20C Overview: Classic and Novel Targets, Pathogenic Variants and Raine Syndrome Phenotypes. International Journal of Molecular Sciences. Published July 2021. https://doi.org/10.3390/ijms22158039. (palmalara2021fam20coverviewclassic pages 16-17, palmalara2021fam20coverviewclassic pages 1-2)
• Ishikawa et al. The Raine Syndrome Protein FAM20C Is a Golgi Kinase That Phosphorylates Bio-Mineralization Proteins. PLOS ONE. Published 13 August 2012. https://doi.org/10.1371/journal.pone.0042988. (palmalara2023potentialroleof pages 1-2)

PMIDs were not exposed in the retrieved records for these papers; DOIs and publication dates are therefore supplied rather than risking incorrect PMID assignment.

References

1. (costa2024gingivalproteomicsreveals pages 1-2): Cláudio Rodrigues Rezende Costa, Rym Chalgoumi, Amina Baker, Clément Guillou, Paulo Marcio Yamaguti, Victor Simancas Escorcia, Lilia Abbad, Bruna Rabelo Amorin, Caroline Lourenço de Lima, Vidjea Cannaya, Mourad Benassarou, Ariane Berdal, Christos Chatziantoniou, Olivier Cases, Pascal Cosette, Renata Kozyraki, and Ana Carolina Acevedo. Gingival proteomics reveals the role of tgf beta and yap/taz signaling in raine syndrome fibrosis. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-59713-0, doi:10.1038/s41598-024-59713-0. This article has 5 citations and is from a peer-reviewed journal.

2. (palmalara2021fam20coverviewclassic pages 1-2): Icela Palma-Lara, Monserrat Pérez-Ramírez, Patricia García Alonso-Themann, Ana María Espinosa-García, Ricardo Godinez-Aguilar, José Bonilla-Delgado, Adolfo López-Ornelas, Georgina Victoria-Acosta, María Guadalupe Olguín-García, José Moreno, and Carmen Palacios-Reyes. Fam20c overview: classic and novel targets, pathogenic variants and raine syndrome phenotypes. International Journal of Molecular Sciences, 22:8039, Jul 2021. URL: https://doi.org/10.3390/ijms22158039, doi:10.3390/ijms22158039. This article has 35 citations.

3. (palmalara2023potentialroleof pages 1-2): Icela Palma-Lara, Patricia García Alonso-Themann, Javier Pérez-Durán, Ricardo Godínez-Aguilar, José Bonilla-Delgado, Damián Gómez-Archila, Ana María Espinosa-García, Manuel Nolasco-Quiroga, Georgina Victoria-Acosta, Adolfo López-Ornelas, Juan Carlos Serrano-Bello, María Guadalupe Olguín-García, and Carmen Palacios-Reyes. Potential role of protein kinase fam20c on the brain in raine syndrome, an in silico analysis. International Journal of Molecular Sciences, 24:8904, May 2023. URL: https://doi.org/10.3390/ijms24108904, doi:10.3390/ijms24108904. This article has 3 citations.

4. (costa2024gingivalproteomicsreveals pages 2-3): Cláudio Rodrigues Rezende Costa, Rym Chalgoumi, Amina Baker, Clément Guillou, Paulo Marcio Yamaguti, Victor Simancas Escorcia, Lilia Abbad, Bruna Rabelo Amorin, Caroline Lourenço de Lima, Vidjea Cannaya, Mourad Benassarou, Ariane Berdal, Christos Chatziantoniou, Olivier Cases, Pascal Cosette, Renata Kozyraki, and Ana Carolina Acevedo. Gingival proteomics reveals the role of tgf beta and yap/taz signaling in raine syndrome fibrosis. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-59713-0, doi:10.1038/s41598-024-59713-0. This article has 5 citations and is from a peer-reviewed journal.

5. (OpenTargets Search: Raine syndrome-FAM20C): Open Targets Query (Raine syndrome-FAM20C, 1 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (palmalara2021fam20coverviewclassic pages 16-17): Icela Palma-Lara, Monserrat Pérez-Ramírez, Patricia García Alonso-Themann, Ana María Espinosa-García, Ricardo Godinez-Aguilar, José Bonilla-Delgado, Adolfo López-Ornelas, Georgina Victoria-Acosta, María Guadalupe Olguín-García, José Moreno, and Carmen Palacios-Reyes. Fam20c overview: classic and novel targets, pathogenic variants and raine syndrome phenotypes. International Journal of Molecular Sciences, 22:8039, Jul 2021. URL: https://doi.org/10.3390/ijms22158039, doi:10.3390/ijms22158039. This article has 35 citations.

7. (costa2024gingivalproteomicsreveals pages 21-22): Cláudio Rodrigues Rezende Costa, Rym Chalgoumi, Amina Baker, Clément Guillou, Paulo Marcio Yamaguti, Victor Simancas Escorcia, Lilia Abbad, Bruna Rabelo Amorin, Caroline Lourenço de Lima, Vidjea Cannaya, Mourad Benassarou, Ariane Berdal, Christos Chatziantoniou, Olivier Cases, Pascal Cosette, Renata Kozyraki, and Ana Carolina Acevedo. Gingival proteomics reveals the role of tgf beta and yap/taz signaling in raine syndrome fibrosis. Scientific Reports, Apr 2024. URL: https://doi.org/10.1038/s41598-024-59713-0, doi:10.1038/s41598-024-59713-0. This article has 5 citations and is from a peer-reviewed journal.

8. (zhang2020highphosphatedietimproved pages 11-12): Hua Zhang, Lili Li, Matthew J. Kesterke, Yongbo Lu, and Chunlin Qin. High-phosphate diet improved the skeletal development of fam20c-deficient mice. Cells Tissues Organs, 208:25-36, Feb 2020. URL: https://doi.org/10.1159/000506005, doi:10.1159/000506005. This article has 8 citations and is from a peer-reviewed journal.

9. (palmalara2023potentialroleof pages 26-27): Icela Palma-Lara, Patricia García Alonso-Themann, Javier Pérez-Durán, Ricardo Godínez-Aguilar, José Bonilla-Delgado, Damián Gómez-Archila, Ana María Espinosa-García, Manuel Nolasco-Quiroga, Georgina Victoria-Acosta, Adolfo López-Ornelas, Juan Carlos Serrano-Bello, María Guadalupe Olguín-García, and Carmen Palacios-Reyes. Potential role of protein kinase fam20c on the brain in raine syndrome, an in silico analysis. International Journal of Molecular Sciences, 24:8904, May 2023. URL: https://doi.org/10.3390/ijms24108904, doi:10.3390/ijms24108904. This article has 3 citations.

Artifacts

• Edison artifact artifact-00